...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.
【24h】

Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.

机译:在马凡氏综合征和相关疾病中具有TGFBR2和FBN1突变的患者的临床表现和结局比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: TGFBR2 mutations were recognized recently among patients with a Marfan-like phenotype. The associated clinical and prognostic spectra remain unclear. METHODS AND RESULTS: Clinical features and outcomes of 71 patients with a TGFBR2 mutation (TGFBR2 group) were compared with 50 age- and sex-matched unaffected family members (control subjects) and 243 patients harboring FBN1 mutations (FBN1 group). Aortic dilatation was present in a similar proportion of patients in both the TGFBR2 and FBN1 groups (78% versus 79%, respectively) but was highly variable. The incidence and average age for thoracic aortic surgery (31% versus 27% and 35+/-16 versus 39+/-13 years, respectively) and aortic dissection (14% versus 10% and 38+/-12 versus 39+/-9 years) were also similar in the 2 groups. Mitral valve involvement (myxomatous, prolapse, mitral regurgitation) was less frequent in the TGFBR2 than in the FBN1 group (all P<0.05). Aortic dilatation, dissection, or sudden death was the index event leading to genetic diagnosis in 65% of families with TGFBR2 mutations, versus 32% with FBN1 mutations (P=0.002). The rate of death was greater in TGFBR2 families before diagnosis but similar once the disease had been recognized. Most pregnancies were uneventful (without death or aortic dissection) in both TGFBR2 and FBN1 families (38 of 39 versus 213 of 217; P=1). Seven patients (10%) with a TGFBR2 mutation fulfilled international criteria for Marfan syndrome, 3 of whom presented with features specific for Loeys-Dietz syndrome. CONCLUSIONS: Clinical outcomes appear similar between treated patients with TGFBR2 mutations and individuals with FBN1 mutations. Prognosis depends on clinical disease expression and treatment rather than simply the presence of a TGFBR2 gene mutation.
机译:背景:最近在具有马凡样表型的患者中认识到TGFBR2突变。相关的临床和预后光谱仍然不清楚。方法和结果:将71例TGFBR2突变患者(TGFBR2组)与50例年龄和性别匹配的未受影响家庭成员(对照组)和243例具有FBN1突变的患者(FBN1组)的临床特征和结果进行了比较。在TGFBR2和FBN1组中,主动脉扩张的患者比例相似(分别为78%和79%),但差异很大。胸主动脉手术的发生率和平均年龄(分别为31%对27%和35 +/- 16对39 +/- 13岁)和主动脉解剖(14%对10%和38 +/- 12对39 + / -9岁)在两组中也相似。与FBN1组相比,TGFBR2组的二尖瓣受累(粘液瘤,脱垂,二尖瓣关闭不全)的发生率较低(所有P <0.05)。主动脉扩张,解剖或猝死是导致TGFBR2突变的家庭进行基因诊断的指标事件,而有FBN1突变的家庭占32%(P = 0.002)。在诊断之前,TGFBR2家族的死亡率较高,但一旦识别出该疾病,死亡率相似。在TGFBR2和FBN1家族中,大多数孕妇都平安无事(没有死亡或主动脉夹层)(39个中的38个与217个中的213个; P = 1)。 TGFBR2突变的7例患者(10%)符合Marfan综合征的国际标准,其中3例具有Loeys-Dietz综合征特有的特征。结论:TGFBR2突变的治疗患者和FBN1突变的患者的临床结局相似。预后取决于临床疾病的表达和治疗,而不仅仅是TGFBR2基因突变的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号